Research programme: lipocalin variants - Pieris Pharmaceuticals

Drug Profile

Research programme: lipocalin variants - Pieris Pharmaceuticals

Alternative Names: PRS-342; PRS-343

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Bispecific antibodies; Lipocalins
  • Mechanism of Action CD137 antigen antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Nov 2016 Additional preclinical data presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 26 Sep 2016 Positive preclinical data released by Pieris Pharmaceuticals
  • 07 Sep 2016 Selexis enter into a commercial cell line license agreement with Pieris pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top